About: Karla M. Eggert

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Karla M. Eggert Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	ikertzailea (eu) researcher (en) 연구원 (ko) wetenschapper (nl) дослідник (uk) वैज्ञानिक (hi) изилдөөчү (ky) 研究者 (zh)
rdfs:label	Karla M. Eggert (en) Karla M. Eggert (es) Karla M. Eggert (nl) Karla M. Eggert (ast)
skos:prefLabel	Karla M. Eggert (en) Karla M. Eggert (es) Karla M. Eggert (nl) Karla M. Eggert (ast)
name	Karla M. Eggert (en) Karla M. Eggert (es) Karla M. Eggert (nl) Karla M. Eggert (ast)
instance of	wds:Q67207415-76FD77AA-1D49-49B5-98EC-C2C892AC0EDF
instance of	Homo sapiens
Semantic Scholar author ID	wds:Q67207415-70CD63C5-5AA5-4854-8FDA-AEE13703E9D6
Semantic Scholar author ID	50214454
skos:altLabel	Eggert K (en) K M Eggert (en) K M Eggert (es) K M Eggert (nl) K M Eggert (ast) Karla Eggert (en)
occupation	wds:Q67207415-20D0BE54-2BA7-4B4F-9B00-B73F9F8B2FAA
occupation	researcher
is owl:sameAs of	Karla M. Eggert
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q67207415
is author of	Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: a DTI study using TBSS. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). The European Multiple System Atrophy-Study Group (EMSA-SG). Postprandial ghrelin response is reduced in patients with Parkinson's disease and idiopathic REM sleep behaviour disorder: a peripheral biomarker for early Parkinson's disease? Diurnal variation of hypothalamic function and chronic subthalamic nucleus stimulation in Parkinson's disease Costs of Parkinson's disease in eastern Europe: a Czech cohort study Real-time visualization of altered gastric motility by magnetic resonance imaging in patients with Parkinson's disease Frequency and treatment of depressive symptoms in a Parkinson's disease registry Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German Competence Network on Parkinson's disease. Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial Health-related quality of life in multiple system atrophy. Attitudes and barriers to clinical practice guidelines in general and to the guideline on Parkinson's disease. A National Survey of German neurologists in private practice Awareness and knowledge of the clinical practice guideline on Parkinson's disease among German neurologists Real-life evaluations of compliance with mandatory drug safety monitoring exemplified with tolcapone in Parkinson's disease. Rationale for transdermal drug administration in Alzheimer disease Trends in resource utilization for Parkinson's disease in Germany Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study. Does the clinical practice guideline on Parkinson's disease change health outcomes? A cluster randomized controlled trial. Autonomic dysfunction in 3414 Parkinson's disease patients enrolled in the German Network on Parkinson's disease (KNP e.V.): the effect of ageing. Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials Patients with idiopathic rapid-eye-movement sleep behavior disorder show normal gastric motility assessed by the 13C-octanoate breath test. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review Development and evaluation of the Parkinson Psychosis Questionnaire A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease. Glial cell line-derived neurotrophic factor protects dopaminergic neurons from 6-hydroxydopamine toxicity in vitro Role of dopamine transporter SPECT for the practitioner and the general neurologist Data protection in biomaterial banks for Parkinson's disease research: the model of GEPARD (Gene Bank Parkinson's Disease Germany). Nigrostriatal dysfunction in X-linked dystonia-parkinsonism (DYT3). Health-related quality of life and its determinants in Parkinson's disease: results of an Italian cohort study Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). Brain monoamine systems in multiple system atrophy: a positron emission tomography study. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease Health-related quality of life in multiple system atrophy and progressive supranuclear palsy Cost effectiveness of pharmacotherapies in early Parkinson's disease Costs of drug treatment in Parkinson's disease Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy The prevalence of the G2019S and R1441C/G/H mutations in LRRK2 in German patients with Parkinson's disease Clinical risk-benefit assessment of dopamine agonists Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes Cost-of-illness in multiple system atrophy and progressive supranuclear palsy Differentially expressed gene profile in the 6-hydroxy-dopamine-induced cell culture model of Parkinson's disease Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study Safety and efficacy of tolcapone in the long-term use in Parkinson disease: an observational study Parkinson's disease: cost-of-illness in an outpatient cohort Akinetic crisis caused by rectus sheath hematoma and acute anemia due to subcutaneous administration of apomorphine Experimental pain sensitivity in multiple system atrophy and Parkinson's disease at an early stage The GEPARD Data Collection Model – Protected Data Collection for the Gene Bank Parkinson's Disease Germany of the Competence Network on Parkinson's Disease (Datenerfassung in GEPARD – Die geschützte Datensammlung der Genbank Parkinson'sche Krank Nigrostriatal upregulation of 5-HT2A receptors correlates with motor dysfunction in progressive supranuclear palsy MSA-QoL: disease-specific questionnaire to assess health-related quality of life in multiple system atrophy: validation of the German translation Erratum to: The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. The Competence Network Parkinson (CNP) Intrathecal application of autologous bone marrow cell preparations in Parkinsonian syndromes.
is author of	wds:Q45909246-B1476072-9450-499E-9490-552772A32550 wds:Q47666154-602501FF-E765-43D3-85B9-2701A578A266 wds:Q40557591-BD841AA6-A3C2-421A-9C90-EB945A8AC607 wds:Q48232317-C1D9D33A-62E2-4ABA-8DB3-ABC616EF9D00

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software